Related Experiment Video
Updated: Jul 12, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
12.4K
Potential bladder cancer therapeutic delivery systems: a recent update.
Oluwadamilola M Kolawole1, Vitaliy V Khutoryanskiy2
1Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Expert Opinion on Drug Delivery
|August 23, 2024
Summary
Developing advanced drug delivery systems, like functionalized nanoparticles in gelling systems, offers improved bladder cancer treatment with controlled release and tumor targeting. Future research may involve combination therapies and smart nanomaterials for better patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery Systems
Background:
- Bladder cancer treatment is costly due to therapy and surveillance needs.
- There's a critical demand for effective, targeted drug formulations to improve patient prognosis.
- Current treatments face challenges in drug release control and tumor specificity.
Purpose of the Study:
- To review drug formulations for bladder cancer treatment over the past decade.
- To highlight recent advancements, clinical trials, and FDA-approved drugs.
- To identify barriers hindering the clinical translation of promising drug delivery systems.
Main Methods:
- Review of scientific literature on bladder cancer drug formulations.
- Analysis of recent trends in bladder cancer treatment strategies.
- Examination of clinical trial data and regulatory approvals.
Main Results:
- Surface-functionalized nanoparticles in in situ gelling systems enhance controlled drug release.
- These advanced systems show potential for improved bladder cancer treatment prognosis.
- Challenges remain in translating laboratory research into clinical applications.
Conclusions:
- Particulate drug delivery systems with surface functionalization and in situ gelling show promise for bladder cancer.
- Future directions include multi-drug systems and smart nanomaterials like photothermal therapies.
- Overcoming translational barriers is key to improving therapeutic outcomes for bladder cancer patients.
Keywords:
Bladder cancerFDA approvalclinical trialsin vitro and in vivo evaluationpreclinicaltherapeutic delivery systemMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...